Aditxt's Q3 Net Loss Widens to $24.2M Amid Revenue Collapse, Evofem Impairment

Ticker: ADTX · Form: 10-Q · Filed: Nov 18, 2025 · CIK: 1726711

Sentiment: bearish

Topics: Biotechnology, Going Concern, Net Loss, Revenue Decline, Asset Impairment, Dilution Risk, Micro-cap

TL;DR

**ADTX is a burning dumpster fire with no revenue and a massive loss; get out now.**

AI Summary

Aditxt, Inc. (ADTX) reported a significant net loss of $24.21 million for the three months ended September 30, 2025, a substantial increase from the $6.98 million net loss in the same period of 2024. Revenue plummeted to $748 for the quarter, down from $6,854 in Q3 2024, and for the nine months, revenue was $2,770, a drastic decrease from $130,810 in the prior year. The company's gross profit was a mere $16 for the quarter, compared to a gross loss of $460,682 in Q3 2024. A major contributing factor to the increased net loss was a $23.00 million impairment of Evofem F-1 Preferred Stock and a $350,000 credit loss on Evofem notes during the nine months ended September 30, 2025. Total assets decreased sharply from $32.14 million at December 31, 2024, to $11.80 million at September 30, 2025, primarily due to a significant reduction in the investment in Evofem from $27.28 million to $7.05 million. The company's accumulated deficit widened to $205.11 million by September 30, 2025, from $168.09 million at December 31, 2024, and it continues to operate with a significant stockholders' deficit of $8.86 million. Aditxt also issued a significant number of common shares through registered direct offerings and an equity line of credit, leading to potential dilution for existing shareholders.

Why It Matters

Aditxt's dire financial state, marked by a massive net loss and near-zero revenue, signals extreme risk for investors. The significant impairment of its Evofem investment and a growing accumulated deficit raise serious going concern doubts, making it highly unlikely for the company to deliver shareholder value in the near term. For employees, this financial instability could lead to job insecurity, while customers might face uncertainty regarding product development and support. In the competitive biotech landscape, Aditxt's inability to generate meaningful revenue or secure stable funding puts it at a severe disadvantage against better-capitalized rivals, potentially leading to its eventual failure.

Risk Assessment

Risk Level: high — Aditxt's risk level is high due to its stated 'going concern' doubt, an accumulated deficit of $205.11 million, and negligible revenue of $748 for the quarter. The company also reported a $23.00 million impairment of Evofem F-1 Preferred Stock, indicating significant asset value destruction.

Analyst Insight

Investors should avoid Aditxt (ADTX) given its severe financial distress, including minimal revenue, substantial losses, and explicit going concern warnings. Existing shareholders should consider divesting to mitigate further losses, as the company's path to profitability appears highly uncertain.

Financial Highlights

debt To Equity
N/A
revenue
$748
operating Margin
N/A
total Assets
$11.80M
total Debt
N/A
net Income
-$24.21M
eps
N/A
gross Margin
N/A
cash Position
$163,041
revenue Growth
-88.9%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales$748-88.9%
Product Sales (Nine Months)$2,770-97.9%

Key Numbers

Key Players & Entities

FAQ

What were Aditxt's key financial results for the quarter ended September 30, 2025?

Aditxt, Inc. reported a net loss of $24,207,669 for the three months ended September 30, 2025, significantly wider than the $6,980,313 net loss in the prior year. Revenue for the quarter was only $748, a sharp decline from $6,854 in Q3 2024.

Why did Aditxt's net loss increase so dramatically in Q3 2025?

The dramatic increase in Aditxt's net loss was primarily driven by a $23,001,919 impairment of Evofem F-1 Preferred Stock and a $350,000 credit loss on Evofem notes, both recorded during the nine months ended September 30, 2025.

What is Aditxt's current cash position and how has it changed?

As of September 30, 2025, Aditxt's cash balance was $163,041. This represents a substantial decrease from $833,031 at December 31, 2024, indicating a rapid depletion of cash reserves.

Does Aditxt have a 'going concern' issue?

Yes, Aditxt explicitly states in its cautionary note that its 'financial situation creates doubt whether we will continue as a going concern,' reflecting significant financial instability and uncertainty about its future operations.

How has Aditxt's investment in Evofem changed?

Aditxt's investment in Evofem decreased significantly from $27,277,211 at December 31, 2024, to $7,051,933 at September 30, 2025, largely due to the $23,001,919 impairment of Evofem F-1 Preferred Stock.

What is the impact of Aditxt's equity offerings on shareholders?

Aditxt has issued a significant number of common shares through registered direct offerings and an equity line of credit, and has agreements for up to $150 million and $35 million in future common stock sales. This could result in significant dilution for existing shareholders.

What are the primary risks Aditxt faces according to the filing?

Key risks include no significant revenue from commercial sales, uncertainty of future profitability, the need for additional capital which may not be available or could be dilutive, and substantial delays or failures in regulatory approval and commercialization of product candidates.

How much was Aditxt's accumulated deficit as of September 30, 2025?

Aditxt's accumulated deficit reached $205,107,091 as of September 30, 2025, an increase from $168,094,569 at December 31, 2024, indicating a growing history of losses.

What is Aditxt's strategy for generating future revenue?

The filing indicates Aditxt's future profitability is uncertain and dependent on obtaining regulatory approval and successfully commercializing product candidates, such as those related to its AditxtScore platform, from which it has generated no significant revenue to date.

What is the total stockholders' equity (deficit) for Aditxt?

As of September 30, 2025, Aditxt reported a total stockholders' deficit of $8,859,178, a significant decline from a positive stockholders' equity of $1,091,396 at December 31, 2024.

Risk Factors

Industry Context

Aditxt operates within the highly competitive and capital-intensive biotechnology sector. This industry is characterized by long development cycles, significant research and development costs, and a high rate of failure. Companies often rely on external funding through equity offerings or partnerships to advance their pipelines. The landscape includes established pharmaceutical giants and numerous smaller, innovative biotech firms, making market penetration and differentiation challenging.

Regulatory Implications

As a publicly traded entity, Aditxt is subject to the oversight of the Securities and Exchange Commission (SEC). This includes rigorous requirements for financial reporting, disclosure of material information, and adherence to accounting standards. Failure to comply can result in investigations, penalties, and reputational damage, impacting investor confidence and access to capital markets.

What Investors Should Do

  1. Monitor cash burn and liquidity runway.
  2. Evaluate the impact of future share issuances.
  3. Assess the recovery potential of the Evofem investment.
  4. Scrutinize the operational strategy and path to profitability.
  5. Review any updates on legal proceedings.

Key Dates

Glossary

Accumulated Deficit
The total net losses of a company that have not been offset by net income since its inception. It represents a negative balance in retained earnings. (Aditxt's accumulated deficit has grown to $205.11 million, highlighting persistent unprofitability.)
Stockholders' Deficit
Occurs when a company's total liabilities exceed its total assets, resulting in a negative net worth for shareholders. (Aditxt has a stockholders' deficit of $8.86 million, indicating that the value of its assets is less than its liabilities, and shareholders have no equity.)
Impairment
A reduction in the carrying value of an asset on a company's balance sheet when its fair value falls below its book value. This often results in a non-cash charge to earnings. (The $23.00 million impairment of Evofem F-1 Preferred Stock is a significant non-cash expense that negatively impacted the company's net loss.)
Registered Direct Offering
A type of public offering where a company sells newly issued securities directly to a small group of institutional investors, often at a discount. (Aditxt has utilized registered direct offerings, which can lead to significant dilution of existing shareholders' equity.)
Equity Line of Credit (ELOC)
An agreement where an investor commits to purchase a certain amount of a company's stock over time at prevailing market prices, providing flexible access to capital. (Aditxt has an ELOC agreement for up to $150 million, which represents potential future dilution.)
At The Market (ATM) Offering
A type of equity offering where a company sells shares directly into the open market over a period of time, typically through an underwriter. (Aditxt has an ATM offering agreement for up to $35 million, indicating further potential for share dilution.)
Gross Profit
Revenue minus the cost of goods sold. It represents the profit a company makes after deducting the direct costs associated with producing its goods or services. (Aditxt reported a gross profit of $16 for the quarter, a stark contrast to a gross loss in the prior year, though the revenue base is extremely small.)
Mandatorily Redeemable Preferred Stock
A class of preferred stock that the issuer is obligated to redeem (buy back) from the holder at a specified future date or upon the occurrence of a specific event. (The company has significant amounts of Mandatorily Redeemable A-1 and C-1 Preferred Stock, which represent future cash outflows or equity conversions.)

Year-Over-Year Comparison

Compared to the prior year's filing, Aditxt has experienced a catastrophic decline in revenue, with Q3 2025 sales at $748 versus $6,854 in Q3 2024. The net loss has widened dramatically from $6.98 million to $24.21 million. Total assets have shrunk from $32.14 million to $11.80 million, largely due to a significant reduction in the Evofem investment. A new risk factor has emerged concerning the substantial impairment of the Evofem investment, and the company's financial health is further strained by a growing stockholders' deficit and increased dilution risk from recent equity offerings.

Filing Stats: 4,911 words · 20 min read · ~16 pages · Grade level 20 · Accepted 2025-11-17 17:46:54

Key Financial Figures

Filing Documents

FINANCIAL

PART I FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements 6 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 32 Item 3. Quantitative and Qualitative Disclosures About Market Risk 45 Item 4. Controls and Procedures 45 PART II OTHER INFORMATION Item 1. Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3. Defaults Upon Senior Securities 47 Item 4. Mine Safety Disclosures 48 Item 5. Other Information 48 Item 6. Exhibits 48

Signatures

Signatures 49 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements may be identified by such forward-looking terminology as "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: we have generated no significant revenue from commercial sales to date and our future profitability is uncertain; if we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment; our financial situation creates doubt whether we will continue as a going concern; we may need to raise additional funding, which may not be available on acceptable terms, or at all; even if we can raise additional funding, we may be required to do so on terms that are dilutive to you. the regulatory approval process is expensive, time-consuming and uncertain and may preve

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ADITXT, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash $ 163,041 $ 833,031 Accounts receivable, net 39,182 43,435 Inventory 6,572 11,245 Prepaid expenses 62,616 3,379 Subscription receivable 149,027 1,108,751 TOTAL CURRENT ASSETS 420,438 1,999,841 Fixed assets, net 1,345,310 1,547,774 Intangible assets, net 3,611 6,111 Deposits 244,698 87,672 Right of use asset 703,482 1,225,781 Notes receivable, net of discount and allowance 1,954,938 - Investment in Evofem 7,051,933 27,277,211 Other assets 75,229 - TOTAL ASSETS $ 11,799,639 $ 32,144,390 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) CURRENT LIABILITIES: Accounts payable and accrued expenses $ 11,558,134 $ 13,212,239 Mandatorily Redeemable A-1 Preferred Stock ( 939 and 0 shares) 1,079,047 - Mandatorily Redeemable C-1 Preferred Stock ( 1,987 and 1,178 shares) 2,285,407 1,354,774 Stock payable - 2,250,000 Notes payable, related party 185,000 115,000 Notes payable, net of discount 4,699,694 5,537,860 Financing on fixed assets 147,823 147,823 Deferred rent 62,046 106,075 Lease liability, current 641,436 683,352 TOTAL CURRENT LIABILITIES 20,658,587 23,407,123 Lease liability, long term - 436,354 Derivative liability 230 14,517 TOTAL LIABILITIES 20,658,817 23,857,994 COMMITMENTS AND CONTINGENCIES MEZZANINE EQUITY Series C-1 Convertible Preferred stock, $ 0.001 par value, 10,853 shares authorized, zero and 8,373 shares issued and outstanding, respectively - 7,195,000 TOTAL MEZZANINE EQUITY - 7,195,000 STOCKHOLDERS' EQUITY (DEFICIT) Preferred stock, $ 0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively - - Series A-1 Convertible Preferred stock, $ 0.001 par value, 22,280 shares authorized, 20,864 and 22,071 shares issued and outstanding, respectivel

financial statements

financial statements. 3 ADITXT, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (Unaudited) Preferred A-1 Shares Preferred A-1 Shares Par Preferred B-1 Shares Preferred B-1 Shares Par Preferred B-2 Shares Preferred B-2 Shares Par Preferred C-1 Shares Preferred C-1 Shares Par Preferred D-1 Shares Preferred D-1 Shares Par Common Shares Outstanding Common Shares Par Treasury Stock Additional Paid-in Capital Accumulated Deficit Non- Controlling Interest Total Stockholders' Equity Balance December 31, 2023 22,280 $ 22 - $ - 2,625 $ 3 - $ - - $ - 41 $ 11 $ ( 201,605 ) $ 143,999,018 $ ( 127,741,072 ) $ ( 9,608 ) $ 16,046,769 Stock option compensation - - - - - - - - - - - - - 24,573 - - 24,573 MDNA asset purchase - - - - - - - - - - 1 1 - 1,008,668 - - 1,008,669 Brain asset purchase - - 6,000 6 - - - - - - - - - 5,970,437 - - 5,970,443 Issuance of shares for settlement - - - - - - - - - - 1 1 - 1,599,999 - - 1,600,000 Net loss - - - - - - - - - - - - - - ( 14,729,727 ) ( 138,967 ) ( 14,868,694 ) Balance March 31, 2024 22,280 $ 22 6,000 $ 6 2,625 $ 3 - $ - - $ - 43 $ 13 $ ( 201,605 ) $ 152,602,695 $ ( 142,470,799 ) $ ( 148,575 ) $ 9,781,760 Stock option compensation - - - - - - - - - - - - - 4,095 - - 4,095 Restricted stock unit compensation - - - - - - - - - - 1 - - 2 - - 2 Issuance of shares for offering, net of issuance costs - - - - - - 4,186 4 4,186 4 - - - 3,518,559 - - 3,518,567 Issuance of shares for debt issuance costs - - - - - - - - - - 1 1 - 662,717 - - 662,718 Modification of warrants - - - - - - - - - - - - - 4,137 ( 4,137 ) - - Net loss - - - - - - - - - - - - - - ( 7,549,619 ) ( 74,260 ) ( 7,623,879 ) Balance June 30, 2024 22

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Overview Aditxt, Inc. is an i

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing